Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Biology Company Intrexon Raises $150M in Series F Preferred Investment Round

NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon said late Wednesday that it has closed a Series F preferred investment round that raised $150 million.

Proceeds from the financing round will be used for working capital to establish additional channel collaborations in the firm's core sectors, including healthcare, food, energy, and environment, it said, adding that funding will also be used for further development of its technology platforms and expansion of its sales and marketing and R&D efforts.

New investors accounted for the majority of funding in the round. Current investors, including affiliates of Intrexon Chairman and CEO Randal Kirk, as well as Third Security, also participated.

In total, the Germantown, Md.-based firm has raised $509 million, it said. About two years ago, it raised $100 million in a Series E round, and in January 2010 it raised $25 million.

"The Intrexon team is committed to delivering results for all of our collaborations," Kirk said in a statement. "With our proprietary technology platforms, we are helping our collaborators discover, design, develop, and ultimately bring to market genetically enhanced products that hold remarkable promise."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.